gemfibrozil has been researched along with Blood Pressure, High in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus." | 9.10 | Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002) |
| "This study investigated the possible synergistic role of obesity in hypertension-induced cardiac remodeling and its modulation by gemfibrozil treatment in rats." | 7.77 | Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. ( Krishan, P; Singh, AP; Singh, M; Singh, R, 2011) |
| "To report a case of rhabdomyolysis and acute renal failure associated with gemfibrozil monotherapy of hyperlipidemia." | 7.72 | Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. ( Layne, RD; Sehbai, AS; Stark, LJ, 2004) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 6.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| "To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus." | 5.10 | Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002) |
| "This study investigated the possible synergistic role of obesity in hypertension-induced cardiac remodeling and its modulation by gemfibrozil treatment in rats." | 3.77 | Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. ( Krishan, P; Singh, AP; Singh, M; Singh, R, 2011) |
| "To report a case of rhabdomyolysis and acute renal failure associated with gemfibrozil monotherapy of hyperlipidemia." | 3.72 | Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. ( Layne, RD; Sehbai, AS; Stark, LJ, 2004) |
| " The three groups were similar for age, sex and geographical region, but significantly more patients on bezafibrate had diabetes and/or hypertension than those on gemfibrozil or simvastatin." | 3.70 | A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). ( Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999) |
| "Gemfibrozil treatment was associated with 3% to 6% decreases in the small, lipid-poor prebeta-1 HDL and in the large, lipid-rich alpha-1 and alpha-2 HDL and with increases in the small alpha-3 (3%) and prealpha-3 (16%) HDLs." | 2.73 | Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. ( Asztalos, BF; Bloomfield, HE; Collins, D; Horvath, KV; Robins, SJ; Schaefer, EJ, 2008) |
| "Treatment with simvastatin or gemfibrozil in hypertensive patients in hydrochlorothiazide monotherapy can reduce total cholesterol and LDL-cholesterol plasma levels, while significantly increasing HDL plasma levels compared to placebo." | 2.67 | [Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide]. ( Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, R | 1 |
| Singh, AP | 1 |
| Singh, M | 1 |
| Krishan, P | 1 |
| Kervinen, H | 1 |
| Huittinen, T | 1 |
| Vaarala, O | 1 |
| Leinonen, M | 1 |
| Saikku, P | 1 |
| Manninen, V | 2 |
| Mänttäri, M | 2 |
| Layne, RD | 1 |
| Sehbai, AS | 1 |
| Stark, LJ | 1 |
| Borghi, C | 1 |
| Dormi, A | 1 |
| Veronesi, M | 1 |
| Sangiorgi, Z | 1 |
| Gaddi, A | 1 |
| Sigal, R | 2 |
| Malcolm, J | 2 |
| Meggison, H | 1 |
| Arnaout, A | 1 |
| Guzik, TJ | 1 |
| Harrison, DG | 1 |
| Asztalos, BF | 1 |
| Collins, D | 1 |
| Horvath, KV | 1 |
| Bloomfield, HE | 1 |
| Robins, SJ | 1 |
| Schaefer, EJ | 1 |
| Virkkunen, H | 1 |
| Härmä, M | 1 |
| Kauppinen, T | 1 |
| Tenkanen, L | 1 |
| Tiula, E | 1 |
| Alikoski, T | 1 |
| Van Buren, CT | 1 |
| Górriz, JL | 1 |
| Sancho, A | 1 |
| Lopez-Martin, JM | 1 |
| Alcoy, E | 1 |
| Catalán, C | 1 |
| Pallardó, LM | 1 |
| Andrews, TC | 1 |
| Whitney, EJ | 1 |
| Green, G | 1 |
| Kalenian, R | 1 |
| Personius, BE | 1 |
| Beggs, PW | 1 |
| Clark, DW | 1 |
| Williams, SM | 1 |
| Coulter, DM | 1 |
| Whitelaw, DC | 1 |
| Smith, JM | 1 |
| Nattrass, M | 1 |
| Berioli, S | 1 |
| Bentivoglio, M | 1 |
| Conti, R | 1 |
| Osanna, RA | 1 |
| Savino, K | 1 |
| Zollino, L | 1 |
| Corea, L | 1 |
| Oliver, MF | 1 |
2 reviews available for gemfibrozil and Blood Pressure, High
| Article | Year |
|---|---|
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Corona | 2004 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid | 2006 |
7 trials available for gemfibrozil and Blood Pressure, High
| Article | Year |
|---|---|
Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Antihype | 2004 |
Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Topics: Cardiovascular Diseases; Coronary Disease; Gemfibrozil; Humans; Hypertension; Hypolipidemic Agents; | 2008 |
Effects of hypertension and dyslipidemia on the decline in renal function.
Topics: Adult; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Creatin | 1995 |
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Co | 1997 |
Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind | 2002 |
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide | 1990 |
Strategy, yield and risks of controlling plasma lipids in the primary prevention of coronary heart disease.
Topics: Adult; Arteriosclerosis; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet; | 1985 |
8 other studies available for gemfibrozil and Blood Pressure, High
| Article | Year |
|---|---|
Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats.
Topics: Animals; Aorta, Abdominal; Blood Pressure; Cardiomegaly; Dietary Fats; Gemfibrozil; Glutathione; Hea | 2011 |
Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk.
Topics: Antibodies; Chaperonin 60; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypertension; Hyp | 2003 |
Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy.
Topics: Acute Kidney Injury; Adult; Creatinine; Diabetes Mellitus, Type 1; Gemfibrozil; Humans; Hyperlipidem | 2004 |
Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?
Topics: Albuminuria; Angiotensin II; Animals; Atherosclerosis; Endothelium, Vascular; Fibrosis; Gemfibrozil; | 2007 |
Shift work, occupational noise and physical workload with ensuing development of blood pressure and their joint effect on the risk of coronary heart disease.
Topics: Adult; Blood Pressure; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; Hypertension; Hypol | 2007 |
Hyperlipidemia and hypertension: impact of steroid withdrawal.
Topics: Adrenal Cortex Hormones; Cholestyramine Resin; Female; Gemfibrozil; Heart Transplantation; Humans; H | 1993 |
Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy.
Topics: Acute Kidney Injury; Aged; Angiotensin-Converting Enzyme Inhibitors; Bicarbonates; Diabetes Mellitus | 1996 |
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Topics: Bezafibrate; Cohort Studies; Comorbidity; Diabetes Complications; Female; Gemfibrozil; Humans; Hyper | 1999 |